Magadh Chronicle

Her2 Positive Breast Cancer Pipeline Landscape Analysis: 75+ Companies and 75+ Pipeline Drugs

 Breaking News
  • No posts were found

Her2 Positive Breast Cancer Pipeline Landscape Analysis: 75+ Companies and 75+ Pipeline Drugs

November 15
21:09 2022
Her2 Positive Breast Cancer Pipeline Landscape Analysis: 75+ Companies and 75+ Pipeline Drugs

DelveInsight’s, HER2 Positive Breast Cancer Pipeline Insight, 2022” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Key takeaways from the HER2 Positive Breast Cancer Pipeline Report

  • DelveInsight’s HER2 Positive Breast Cancer Pipeline analysis depicts a robust space with 75+ active players working to develop 75+ pipeline treatment therapies.
  • The leading HER2 Positive Breast Cancer Companies such as Ambrx, Alteogen, Genentech, Suzhou Zanrong Pharma Limited, AstraZeneca, Shanghai Henlius Biotech, Roche Pharma AG, GeneQuantum Healthcare (Suzhou) Co., Ltd., Klus Pharma Inc., Carisma Therapeutics Inc, Triumvira Immunologics, Inc., Precirix, DualityBio Inc., Seagen Inc., and others.
  • Promising HER2 Positive Breast Cancer Pipeline therapies such as ALT P7, ARX 788, Inavolisib, and others.
  • In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, HER2 Positive Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Recent Developmental Activities in the HER2 Positive Breast Cancer Pipeline Report

  • The US Food and Drug Administration (FDA) has granted Fast Track Designation for ARX788 in HER2+ metastatic breast cancer and Orphan Drug Designation for ARX788 in gastric cancer. ARX788 is a homogeneous and highly stable ADC, which targets the HER2 receptor and contains two AS269 cytotoxic payloads site-specifically conjugated to a trastuzumab-based antibody.
  • The PI3K/Akt/mTOR pathway regulates cell growth and survival. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of HER2-positive Breast Cancer.
  • Alteogen is using NexMab™ ADC technology to develop ALT-P7, a targeted breast / gastric cancer drug. ALT-P7 is an anti-HER2 targeting ADC utilizing NexMab™ ADC technology. ALT-P7’s payload drugs are site specifically conjugated to the HER2 targeted antibody, whereas Kadcyla has drug payloads conjugated, on a non-site specific manner, to the HER2 targeted antibody. Because of the site-specific conjugation, ALT-P7 can be developed as safer and better alternative anti-cancer drug than Kadcyla. A phase I clinical trial is being completed and phase II clinical trial will soon be held.

Request a sample and discover the recent advances in HER2 Positive Breast Cancer Medication @ HER2 Positive Breast Cancer Clinical Trials

HER2 Positive Breast Cancer Overview

HER2-positive breast cancer is when breast cancer cells have a protein receptor called HER2 (human epidermal growth factor receptor 2). Normally, this protein helps breast cells grow, divide, and repair themselves. But sometimes, something goes wrong in the gene that controls the HER2 protein and the body makes too many of these receptors. This causes the breast cells to grow and divide uncontrollably. About 1 of 5 breast cancers are HER2-positive.While HER2 is more aggressive than other types of breast cancer, there are treatments that can help. A lump in the breast that feels different from the area around it is the most common symptom of breast cancer. Other symptoms of HER2-positive breast cancer can include: Breast swelling, a change in its shape, skin irritation or dimpling, pain in the breast or nipple, redness or thickness of the nipple or breast skin and discharge from the nipple (not breast milk). Doctors don’t know the exact causes of breast cancer. Experts think it may be a combination of things, including genes, environment, and lifestyle. If patient is diagnosed with breast cancer, the doctor will check to see if it is HER2-positive. They’ll probably give patient one or more of these tests: The IHC test uses certain antibodies that identify the HER2 protein in a sample of breast cancer tissue, the FISH test uses fluorescent pieces of DNA that stick to the HER2 gene in cells, which can then be counted under a microscope and the Inform Dual ISH test uses stains that color HER2 genes in a tissue sample so they can be counted under a microscope. HER2-positive (HER2+) breast cancers constitute an aggressive type of breast cancer and tend to grow faster and are more likely to spread. However, therapies that specifically target HER2, such as Herceptin® (traztuzumab), are very effective. HER2 targeted therapies, has significantly improved the therapeutic outcome for patients with HER2 positive breast cancer.

HER2 Positive Breast Cancer Emerging Drugs

  • ALT P7: Alteogen
  • ARX 788: Ambrx
  • Inavolisib: Genentech

HER2 Positive Breast Cancer Pipeline Therapeutics Analysis

There are approx. 75+ key companies which are developing the therapies for HER2 Positive Breast Cancer. The companies which have their HER2 Positive Breast Cancer drug candidates in the most advanced stage, i.e. phase II /III include, Ambrx.

Learn more about the emerging HER2 Positive Breast Cancer pipeline therapies @ HER2 Positive Breast Cancer Pipeline Outlook

Scope of the HER2 Positive Breast Cancer Pipeline Report

  • Coverage- Global
  • HER2 Positive Breast Cancer Therapeutic Assessment by Product Type
  • HER2 Positive Breast Cancer Therapeutic Assessment by Stage and Product Type
  • HER2 Positive Breast Cancer Therapeutic Assessment by Route of Administration
  • HER2 Positive Breast Cancer Therapeutic Assessment by Stage and Route of Administration
  • HER2 Positive Breast Cancer Therapeutic Assessment by Molecule Type
  • HER2 Positive Breast Cancer Therapeutic Assessment by Stage and Molecule Type
  • HER2 Positive Breast Cancer Companies- Ambrx, Alteogen, Genentech, Suzhou Zanrong Pharma Limited, AstraZeneca, Shanghai Henlius Biotech, Roche Pharma AG, GeneQuantum Healthcare (Suzhou) Co., Ltd., Klus Pharma Inc., Carisma Therapeutics Inc, Triumvira Immunologics, Inc., Precirix, DualityBio Inc., Seagen Inc., and others
  • HER2 Positive Breast Cancer Pipeline therapies- ALT P7, ARX 788, Inavolisib, and others

Table of content

  1. Introduction
  2. Executive Summary
  3. HER2 Positive Breast Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. HER2 Positive Breast Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase II/III)
  8. ARX 788: Ambrx
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Inavolisib: Genentech
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. ALT P7: Alteogen
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. HER2 Positive Breast Cancer Key Companies
  21. HER2 Positive Breast Cancer Key Products
  22. HER2 Positive Breast Cancer- Unmet Needs
  23. HER2 Positive Breast Cancer- Market Drivers and Barriers
  24. HER2 Positive Breast Cancer- Future Perspectives and Conclusion
  25. HER2 Positive Breast Cancer Analyst Views
  26. HER2 Positive Breast Cancer Key Companies
  27. Appendix

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing HER2 Positive Breast Cancer drugs?
  • How many HER2 Positive Breast Cancer drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of HER2 Positive Breast Cancer?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the HER2 Positive Breast Cancer therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for HER2 Positive Breast Cancer and their status?
  • What are the key designations that have been granted to the emerging drugs?

Got Queries? Get in touch with our Business Development Executive @ HER2 Positive Breast Cancer Treatment Landscape

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories